stockrowBoston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
- Revenue
- +1.44%
- EPS
- −21.6%
- Free cash flow
- −25.3%
- Total debt
- +3.04%
Quarter to September 2026, against a year earlier
Follow BSX
Alert me
Boston Scientific Corporation (BSX) Revenue
Boston Scientific Corporation's revenue for fiscal 2025 was $20.1B, up 19.9% from $16.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $21.1B. Over the past ten years it has ranged from $7.5B (fiscal 2015) to $20.1B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Boston Scientific Corporation ranks 5th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $20.1B | 19.87% |
| FY2024 | $16.7B | 17.61% |
| FY2023 | $14.2B | 12.29% |
| FY2022 | $12.7B | 6.68% |
| FY2021 | $11.9B | 19.92% |
| FY2020 | $9.9B | (7.66%) |
| FY2019 | $10.7B | 9.28% |
| FY2018 | $9.8B | 8.57% |
| FY2017 | $9.0B | 7.89% |
| FY2016 | $8.4B | 12.16% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $5.1B | (5.59%) |
| Jun 2026 | $5.4B | 4.59% |
| Mar 2026 | $5.2B | (1.55%) |
| Dec 2025 | $5.3B | 4.34% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ABT Abbott Laboratories compare | $48.2B |
| MDT Medtronic PLC compare | $37.5B |
| SYK Stryker Corporation compare | $26.3B |
| GEHC GE HealthCare Technologies Inc. compare | $21.6B |
| BSX Boston Scientific Corporation | $21.1B |
| PHG Koninklijke Philips N.V. compare | $20.6B |
| EW Edwards Lifesciences Corporation compare | $6.7B |
| STE STERIS plc compare | $6.2B |
| DXCM DexCom, Inc. compare | $5.1B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BSX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement